Cargando…

Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study

We investigated changes in symptoms and quality of life (QoL) in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving the hexanic extract of Serenoa repens (HESr) and compared results with a matched group on watchful waiting (WW)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Alcaraz, Antonio, Gacci, Mauro, Ficarra, Vincenzo, Medina-Polo, José, Salonia, Andrea, Fernández-Gómez, Jesús M., Ciudin, Alexandru, Castro-Díaz, David, Rodríguez-Antolín, Alfredo, Carballido-Rodríguez, Joaquín, Cózar-Olmo, José M., Búcar-Terrades, Santiago, Pérez-León, Noemí, Brenes-Bermúdez, Francisco J., Molero-García, José M., Ledesma, Antonio Fernández-Pro, Herdman, Michael, Manasanch, José, Angulo, Javier C., Group, on behalf of the QUALIPROST Study
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878824/ https://www.ncbi.nlm.nih.gov/pubmed/35207238 http://dx.doi.org/10.3390/jcm11040967

Ejemplares similares

Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
por: Alcaraz, Antonio, et al.
Publicado: (2022)

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
por: Alcaraz, Antonio, et al.
Publicado: (2021)

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
por: Alcaraz, Antonio, et al.
Publicado: (2020)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)
por: Saponaro, Miriam, et al.
Publicado: (2020)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

Is Serenoa repens Effective in the Treatment of Benign Prostatic Hyperplasia?
por: Çeker, Gökhan
Publicado: (2020)

Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study
por: Alcaraz, Antonio, et al.
Publicado: (2016)

Serenoa Repens: Does It have Any Role in the Management of Androgenetic Alopecia?
por: Murugusundram, Sundaram
Publicado: (2009)

A substitute variety for agronomically and medicinally important Serenoa repens (saw palmetto)
por: Jaiswal, Yogini, et al.
Publicado: (2019)

Comparison of the Phytochemical Composition of Serenoa repens Extracts by a Multiplexed Metabolomic Approach
por: Marti, Guillaume, et al.
Publicado: (2019)

Current consensus and controversies on male LUTS/BPH (part one)
por: Foo, Keong Tatt
Publicado: (2017)

Current consensus and controversies on male LUTS/BPH (part two)
por: Foo, Keong Tatt
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Hexanic Extract of Serenoa repens (Permixon(®)): A Review in Symptomatic Benign Prostatic Hyperplasia
por: Blair, Hannah A.
Publicado: (2022)

Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene
por: Minutoli, Letteria, et al.
Publicado: (2014)

Correction to: Hexanic Extract of Serenoa repens (Permixon(®)): A Review in Symptomatic Benign Prostatic Hyperplasia
por: Blair, Hannah A.
Publicado: (2022)

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
por: Cai, Tong, et al.
Publicado: (2020)

Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms
por: De Monte, Celeste, et al.
Publicado: (2014)

Lipomatrix: A Novel Ascorbyl Palmitate-Based Lipid Matrix to Enhancing Enteric Absorption of Serenoa Repens Oil
por: Fratter, Andrea, et al.
Publicado: (2019)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors
por: Kolontarev, Konstantin, et al.
Publicado: (2016)

Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells
por: Sirab, Nanor, et al.
Publicado: (2013)

Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma
por: Silvestri, Ida, et al.
Publicado: (2013)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
por: Roehrborn, C G, et al.
Publicado: (2011)

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis
por: Trivisonno, Leonel Fabrizio, et al.
Publicado: (2021)

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
por: Manohar, Chikka Moga Siddaiah, et al.
Publicado: (2017)

LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations
por: De Nunzio, Cosimo, et al.
Publicado: (2021)

Survivin and NAIP in Human Benign Prostatic Hyperplasia: Protective Role of the Association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study
por: Morgia, Giuseppe, et al.
Publicado: (2017)

The Clinical Impact of Hexanic Extract of Serenoa repens in Men with Prostatic Inflammation: A Post Hoc Analysis of a Randomized Biopsy Study
por: Samarinas, Michael, et al.
Publicado: (2020)

Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH
por: Liao, Xinyang, et al.
Publicado: (2020)

Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
por: Iacono, Fabrizio, et al.
Publicado: (2012)

AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension
por: Xiao, Hengjun, et al.
Publicado: (2016)

WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
por: Kirschner-Hermanns, Ruth, et al.
Publicado: (2019)

Effects of hexanic extract of serenoa repens (permixon(®) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: Latil, Alain, et al.
Publicado: (2015)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands
por: Drake, Marcus J., et al.
Publicado: (2017)

Correction to: Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ai5fvb39949e6vl9j8io76khhc